The role of pro-inflammatory cytokines and immune cells in colorectal carcinoma progression

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1177-1182

  Liu, Huanran ^a   Zhang, Zhen ^a   Tabuchi, Takafumi ^b   Wang, Shouyu ^a   Wang, Jiangning ^c  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinoma; Cytokine; Granulocyte colony stimulating factor; Granulocyte lymphocyte ratio; Interleukin 6; Macrophage colony stimulating factor

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84874416897     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1176     Document Type: Article

References (32)

1. Schoenfeld J, Jinushi M, Nakazaki Y, et al: Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 70: 10150-10160, 2010.
2. Noori S, Taghikhani M, Hassan ZM, Allameha A and Mostafaei A: Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo. Mol Immunol 47: 1579-1584, 2010.
3. Lesterhuis WJ, Punt CJ, Hato SV, et al: Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 121: 3100-3108, 2011.
4. Wieder T, Braumüller H, Kneilling M, Pichler B and Röcken M: T cell-mediated help against tumors. Cell Cycle 7: 2974-2977, 2008.
5. Forte G, Sorrentino R, Montinaro A, et al: Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol 189: 2226-2233, 2012.
6. Kandasamy M, Bay BH, Lee YK and Mahendran R: Lactobacilli secreting a tumor antigen and IL15 activates neutrophils and dendritic cells and generates cytotoxic T lymphocytes against cancer cells. Cell Immunol 271: 89-96, 2011
7. Schwandt A, Garcia JA, Elson P, et al: Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol 31: 690-698, 2011.
8. Yamamoto M, Kamigaki T, Yamashita K, et al: Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep 22: 337-343, 2009.
9. Kuper H, Adami HO and Trichopoulos D: Infections as a major preventable cause of human cancer. J Intern Med 248: 171-183, 2000.
10. Mareel M and Madani I: Tumour-associated host cells participating at invasion and metastasis: targets for therapy? Acta Chir Belg 106: 635-640, 2006.
11. de Visser KE and Coussens LM: The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13: 118-137, 2006.
12. Kenny PA and Bissell MJ: Tumour reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 107: 688-695, 2003.
13. Revoltella RP, Menicagli M and Campani D: Granulocytemacrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 57: 347-359, 2012.
14. Curran CS, Evans MD and Bertics PJ: GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol 187: 1254-1263, 2011.
15. Liao HH, Wang YC, Chen MC, et al: Down-regulation of granulocyte-macrophage colony-stimulating factor by 3C-like proteinase in transfected A549 human lung carcinoma cells. BMC Immunol 12: 16, 2011.
16. Inoue H, Iga M, Nabeta H, et al: Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci 99: 2315-2326, 2008.
17. Ashizawa T, Okada R, Suzuki Y, et al: Study of interleukin-6 in the spread of colorectal cancer: the diagnostic significance of IL-6. Acta Med Okayama 60: 325-330, 2006.
18. Bao B, Ahmad A, Kong D, et al: Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 7: e43726, 2012.
19. Sato T, Omura M, Saito J, Hirasawa A, Kakuta Y, Wakabayashi Y and Nishikawa T: Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony stimulating factor (M-CSF) and interleukin-6. Thyroid 10: 1113-1118, 2000.
20. Riesco A: Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135-140, 1970.
21. Atzpodien J, Royston P, Wandert T and Reitz M; DGCIN-German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88: 348-353, 2003.
22. Négrier S, Escudier B, Gomez F, et al: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 13: 1460-1468, 2002.
23. Donskov F and von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24: 1997-2005, 2006.
24. Schmidt H, Suciu S, Punt CJ, et al; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951: Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25: 1562-1569, 2007.
25. Liu H, Tabuchi T, Takemura A, et al: The granulocyte/lymphocyte ratio as an independent predictor of tumour growth, metastasis and progression. Mol Med Rep 1: 699-704, 2008.
26. Ietomi K: A study on the role of granulocytes in carcinoma-bearing hosts G/L ratio as a new host indicator. Nippon Gan Chiryo Gakkai Shi 25: 662-671, 1990 (In Japanese).
27. Lee YS, Choi I, Ning Y, et al: Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 106: 1833-1841, 2012.
28. Jung MY, Kim SH, Cho D and Kim TS: Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice. Oncol Rep 22: 1141-1147, 2009.
29. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
30. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD and Strieter RM: Inhibition of interleukin-8 reduces tumori genesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97: 2792-2802, 1996.
31. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
32. Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11: 992-997, 2005.